NZ Bans Avandia Over Cardiovascular Concerns

Law360, New York (February 18, 2011, 1:39 PM EST) -- New Zealand’s health regulator is pulling diabetes drug Avandia from the shelves, saying a safety review found the medication increased patients’ risk of developing cardiovascular problems.

The New Zealand Ministry of Health said Thursday it would suspend Avandia until GlaxoSmithKline, the drug’s manufacturer, could identify a patient population for which the benefits of taking the drug outweighed the risks.

The medicine will be withdrawn from the market April 29, the agency said, adding that the suspension would affect the fewer than 100 people currently taking Avandia...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.